These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9130309)

  • 1. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride.
    Trimble KM; Bell R; King DJ
    Pharmacol Biochem Behav; 1997 Apr; 56(4):809-16. PubMed ID: 9130309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs.
    Weiner I; Shadach E; Barkai R; Feldon J
    Neuropsychopharmacology; 1997 Jan; 16(1):42-50. PubMed ID: 8981387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli.
    Feldon J; Weiner I
    Biol Psychiatry; 1991 Apr; 29(7):635-46. PubMed ID: 2054435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of latent inhibition in the rat at a high dose of clozapine.
    Trimble KM; Bell R; King DJ
    J Psychopharmacol; 1998; 12(2):215-9. PubMed ID: 9694034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of latent inhibition in the rat by the CCK antagonist proglumide.
    Gracey DJ; Bell R; King DJ; Trimble KM; McDermott BJ
    Pharmacol Biochem Behav; 1998 Apr; 59(4):1053-9. PubMed ID: 9586867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphetamine-induced disruption and haloperidol-induced potentiation of latent inhibition depend on the nature of the stimulus.
    Ruob C; Elsner J; Weiner I; Feldon J
    Behav Brain Res; 1997 Oct; 88(1):35-41. PubMed ID: 9401706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the selective dopamine D(1) antagonists NNC 01-0112 and SCH 39166 on latent inhibition in the rat.
    Trimble KM; Bell R; King DJ
    Physiol Behav; 2002 Sep; 77(1):115-23. PubMed ID: 12213509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
    Gaisler-Salomon I; Weiner I
    Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action.
    Weiner I; Schiller D; Gaisler-Salomon I
    Neuropsychopharmacology; 2003 Mar; 28(3):499-509. PubMed ID: 12629529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal.
    Russig H; Murphy CA; Feldon J
    Neuropsychopharmacology; 2002 Jun; 26(6):765-77. PubMed ID: 12007747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat.
    Johansson C; Jackson DM; Svensson L
    Psychopharmacology (Berl); 1994 Dec; 116(4):437-42. PubMed ID: 7701046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin.
    Shadach E; Gaisler I; Schiller D; Weiner I
    Neuropsychopharmacology; 2000 Aug; 23(2):151-61. PubMed ID: 10882841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphetamine-induced disruption of latent inhibition is not reinforcer-mediated.
    Weiner I; Tarrasch R; Bernasconi E; Broersen LM; Rüttimann TC; Feldon J
    Pharmacol Biochem Behav; 1997 Apr; 56(4):817-26. PubMed ID: 9130310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol.
    Hitchcock JM; Lister S; Fischer TR; Wettstein JG
    Behav Brain Res; 1997 Oct; 88(1):43-9. PubMed ID: 9401707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol.
    Schiller D; Zuckerman L; Weiner I
    J Psychiatr Res; 2006 Mar; 40(2):167-77. PubMed ID: 15882871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat.
    Gracey DJ; Bell R; King DJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):497-504. PubMed ID: 11999900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
    Barak S; Weiner I
    Neuropsychopharmacology; 2007 May; 32(5):989-99. PubMed ID: 16971898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine.
    Weiner I; Shadach E; Tarrasch R; Kidron R; Feldon J
    Biol Psychiatry; 1996 Nov; 40(9):834-43. PubMed ID: 8896769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats.
    Weiner I; Feldon J; Katz Y
    Pharmacol Biochem Behav; 1987 Feb; 26(2):241-6. PubMed ID: 3575349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.